Pharmacy Daily | Australian natural health

FLORDIS Natural Medicines (who recently received the first TGA “AUST R” approval for its herbal medicine, Iberogast) and Indonesian pharmaceutical company, the SOHO Group, have collaborated to create a new Australian healthcare company, Soho Flordis International (SFI) Designed as an outlet to develop natural medicine products with ‘high specific evidence’ SFI is a strong advocate of ‘seed to patient control’ meaning that it will implement proceedures that ensure ‘traceability, sustainability and quality of all the steps involved in natural health medicine continuum, from plantation to harvesting, extraction and manufacture’. In addition the company purports that it will place great importance on backing up its natural medicines with evidence. “Patients increasingly expect natural medicine products to deliver proven results,” said Nigel Pollard, ceo of SFI. “Finding such products is now achievable with the increasing availability of published clinical Australian natural health results, independent experts explaining how to select products and the easy access to this information through the internet and better trained health professionals”. As part of its mandate SFI has locked into a partnership with the University of Western Sydney to ‘enhance the specific evidence behind Curcuma xanthorrhiza, an Indonesian herb known as Temulawak’, which is used to treat digestive system complaints. “SFI is already making a significant contribution toward improving the standard of natural health products and we also are looking forward to working with our partners and the global community to acknowledge, reward and translate traditional knowledge on natural medicine,” said Executive chairman of SFI, Eng Liang Tan.

---

The above article was sent to subscribers in Pharmacy Daily's issue from 13 Sep 10
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 13 Sep 10